Min Feng
- Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine 3
- Hepatology top 10%
- Liver physiology and pathology 2
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 4
- Peptidase Inhibition and Analysis 3
-
- Immune Cell Function and Interaction 3
- interferon and immune responses 2
-
- Nanoplatforms for cancer theranostics 5
-
- Autophagy in Disease and Therapy 3
- Journals
- Scientific Reports (1 paper)Journal of Controlled Release (1 paper)International Journal of Cancer (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Min Feng
28 papers receiving 797 citations
Peers
Comparison fields: 5 of 97
- Geriatrics and Gerontology 74
- Cancer Research 140
- Hepatology 71
- Oncology 240
- Immunology 177
Countries citing papers authored by Min Feng
This map shows the geographic impact of Min Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min Feng more than expected).
Fields of papers citing papers by Min Feng
This network shows the impact of papers produced by Min Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min Feng. The network helps show where Min Feng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Min Feng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 5 | |
| 6 | 2021 | 12 | |
| 7 | 2018 | 69 | |
| 8 | 2018 | 81 | |
| 9 | 2018 | 17 | |
| 10 | 2017 | 37 | |
| 11 | High expression of Rap2A is associated with poor prognosis of patients with hepatocellular carcinoma. | 2017 | 11 |
| 12 | 2017 | 50 | |
| 13 | 2016 | 45 | |
| 14 | 2015 | 57 | |
| 15 | 2014 | 22 | |
| 16 | 2013 | 17 | |
| 17 | 2013 | 4 | |
| 18 | 2012 | 38 | |
| 19 | 2012 | 31 | |
| 20 | 2008 | 4 |
About Min Feng
Min Feng is a scholar working on Geriatrics and Gerontology, Biological Psychiatry and Hepatology, having authored 31 papers that have together received 803 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Peptidase Inhibition and Analysis (3 papers), Sirtuins and Resveratrol in Medicine (3 papers), Immune Cell Function and Interaction (3 papers), Autophagy in Disease and Therapy (3 papers), interferon and immune responses (2 papers) and Liver physiology and pathology (2 papers). The work is most often cited by research in Geriatrics and Gerontology (74 citations), Cancer Research (140 citations) and Hepatology (71 citations). Min Feng has collaborated with scholars based in China and United States. Frequent co-authors include Wenxian Guan, Song Liu, Wenxian Guan, Jun Feng, Peng-Fei Yan, Hongyang Zhao, Fangcheng Zhang, Feng Sun, Jie Ding and Jie Zhang. Their work appears in journals such as Scientific Reports, Journal of Controlled Release and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.